Deferiprone

A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.

Also Known As:

1,2-Dimethyl-3-hydroxy-4-pyridinone; 1,2-Dimethyl-3-hydroxypyrid-4-one; 1,2-Dimethyl-3-hydroxypyridin-4-one; 3-Hydroxy-1,2-dimethyl-4-pyridinone; DMOHPO; Ferriprox; HDMPP; 1,2 Dimethyl 3 hydroxy 4 pyridinone; 1,2 Dimethyl 3 hydroxypyrid 4 one; 1,2 Dimethyl 3 hydroxypyridin 4 one; 3 Hydroxy 1,2 dimethyl 4 pyridinone; 4(1H)-Pyridinone, 3-hydroxy-1,2-dimethyl-

Networked: 612 relevant articles (80 outcomes, 119 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Pyridones: 14
      - Deferiprone: 612

Experts

1.	Kontoghiorghes, George J: 36 articles (06/2022 - 01/2002)
2.	Kolnagou, Annita: 20 articles (01/2018 - 01/2002)
3.	Galanello, Renzo: 19 articles (10/2016 - 09/2002)
4.	Tricta, Fernando: 18 articles (03/2022 - 05/2003)
5.	Piga, Antonio: 16 articles (01/2022 - 09/2002)
6.	Spino, Michael: 15 articles (06/2020 - 06/2007)
7.	Fucharoen, Suthat: 13 articles (01/2022 - 01/2006)
8.	Maggio, Aurelio: 12 articles (06/2020 - 03/2002)
9.	Srichairatanakool, Somdet: 10 articles (07/2021 - 01/2006)
10.	Connelly, John: 10 articles (01/2020 - 02/2011)

Related Diseases

1.	Iron Overload 06/01/2020 - "In paediatric patients with transfusion-dependent haemoglobinopathies, deferiprone was effective and safe in inducing control of iron overload during 12 months of treatment. " 11/01/2010 - "This study evaluated the safety and efficacy of a new liquid formulation of deferiprone for the treatment of transfusional iron overload in children 1-10 years old. " 11/01/2010 - "The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload." 01/01/2022 - "The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study." 08/01/2016 - "To study the safety profile of a liquid formulation of deferiprone in chelating young children with transfusion-induced iron overload. "
2.	Thalassemia 01/01/2016 - "Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β-Thalassemia." 04/01/2013 - "Seventy-three pediatric patients with severe β thalassemias, age range 3.2-19 years, were recruited to a 1-year multicenter prospective, single arm, open label, dose escalating Phase III study of deferiprone to determine its clinical efficacy and safety. " 12/01/2012 - "The method was successfully applied to a pharmacokinetic study of deferiprone in six thalassemia patients." 01/01/2022 - "The efficacy and safety profiles of deferiprone were acceptable and consistent with those seen in patients with transfusion-dependent thalassemia. " 12/01/2009 - "In clinical dose of deferiprone, CD results showed that, the alpha-helical content of thalassemia Hb significantly increased. "
3.	beta-Thalassemia (Cooley's Anemia) 03/01/2006 - "Oral deferiprone (L1) appears to be promising in the treatment of beta-thalassemia major (TM) patients. " 03/01/2006 - "Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*." 01/01/2006 - "A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong." 01/01/2018 - "To evaluate the efficacy of prolonged deferiprone monotherapy in patients with b-thalassemia major. " 04/01/2008 - "Our objective was to assess the long-term efficacy of deferiprone in patients with thalassemia major. "
4.	Siderosis 05/01/2022 - "Deferiprone administration significantly improved radiological and clinical outcomes in patients with postoperative superficial siderosis. " 07/09/2013 - "Further studies are required to assess the clinical efficacy of deferiprone in superficial siderosis. " 01/01/2012 - "Prospectively designed efficacy studies are necessary to determine the clinical efficacy of deferiprone in superficial siderosis." 01/01/2012 - "Pilot safety trial of deferiprone in 10 subjects with superficial siderosis." 05/01/2022 - "Fifteen postoperative patients with superficial siderosis were recruited, and seven patients were administered deferiprone (combination therapy group). "
5.	Friedreich Ataxia (Friedreich's Ataxia) 10/01/2014 - "We conducted a 6-month, randomized, double-blind, placebo-controlled study to assess safety, tolerability, and efficacy of deferiprone in Friedreich ataxia (FRDA). " 01/01/2016 - "Clinical Experience With Deferiprone Treatment for Friedreich Ataxia." 10/01/2014 - "Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial." 08/01/2013 - "Deferiprone for the treatment of Friedreich's ataxia." 01/01/2018 - "For patients with Friedreich ataxia, deferiprone possibly worsens ataxia signs over 6 months (1 Class II study). "

Related Drugs and Biologics

1.	Iron
2.	Chelating Agents
3.	Deferoxamine (Desferal)
4.	Deferasirox
5.	Isoflurophate (DFP)
6.	Ferritins (Ferritin)
7.	idebenone
8.	Antioxidants
9.	Free Radicals
10.	1,2-diethyl-3-hydroxypyridin-4-one

Related Therapies and Procedures

1.	Therapeutics
2.	Chelation Therapy (Therapy, Chelation)
3.	Drug Therapy (Chemotherapy)
4.	Complementary Therapies (Alternative Medicine)
5.	Blood Transfusion (Blood Transfusions)